Currently the price of heart stents is capped in India at INR 30,000 and all companies are selling their basic drug eluting stents at or under that price.
If a premium category and corresponding price cap is created for stents like the previous poll's finding suggests, should there be a requirement for any company listing its product in this category to have a product in the basic category on a mandatory basis?
Transforming India Feb 08
Viewed by 8203